MAYNE PHARMA GROUP LIMITED (MYX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MYX - MAYNE PHARMA GROUP LIMITED

Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 22.1
Index: ASX300 | ALL-ORDS

Mayne Pharma is an Australian pharmaceuticals development and manufacturing company with facilities in Australia and the US. It also provides development and manufacturing services to global clients. It listed in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.78

08 Jun
2023

-0.100

OPEN

$3.85

-2.58%

HIGH

$3.88

541,433

LOW

$3.70

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ANP . ARX . AVH . BIO . BNO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . KZA . LGP . MAP . MDC . MSB . MVP . MXC . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . SPL . TLX . TRP . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx-320.0
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx424.8 M
Book Value Per Share xxxxxxxxxxxxxxx640.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-16.6 M
Net Profit Margin xxxxxxxxxxxxxxx-61.99 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx-39.51 %
Return on Invested Capital xxxxxxxxxxxxxxx-32.28 %
Return on Assets xxxxxxxxxxxxxxx-18.94 %
Return on Equity xxxxxxxxxxxxxxx-39.51 %
Return on Total Capital xxxxxxxxxxxxxxx-5.97 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-26.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201720182019202020212022
Short-Term Debt xxxxxxxxxxxxxxx408 M
Long Term Debt xxxxxxxxxxxxxxx6 M
Total Debt xxxxxxxxxxxxxxx414 M
Goodwill - Gross xxxxxxxxxxxxxxx65 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx97 M
Price To Book Value xxxxxxxxxxxxxxx0.78

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201720182019202020212022
Capex xxxxxxxxxxxxxxx11.9 M
Capex % of Sales xxxxxxxxxxxxxxx2.79 %
Cost of Goods Sold xxxxxxxxxxxxxxx319 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx168 M
Research & Development xxxxxxxxxxxxxxx14 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

MYX STOCK CHART